AIMS: Bioactives of Artemisia dracunculus L. (termed PMI 5011) have been shown to improve insulin action by increasing insulin signalling in skeletal muscle. However, it was not known if PMI 5011's effects are retained during an inflammatory condition. We examined the attenuation of insulin action and whether PMI 5011 enhances insulin signalling in the inflammatory environment with elevated cytokines. METHODS: Muscle cell cultures derived from lean, overweight and diabetic-obese subjects were used. Expression of pro-inflammatory genes and inflammatory response of human myotubes were evaluated by real-time polymerase chain reaction (RT-PCR). Insulin signalling and activation of inflammatory pathways in human myotubes were evaluated by multiplex protein assays. RESULTS: We found increased gene expression of monocyte chemoattractant protein 1 (MCP1) and TNFα (tumour necrosis factor alpha), and basal activity of the NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in myotubes derived from diabetic-obese subjects as compared with myotubes derived from normal-lean subjects. In line with this, basal Akt phosphorylation (Ser473) was significantly higher, while insulin-stimulated phosphorylation of Akt (Ser473) was lower in myotubes from normal-overweight and diabetic-obese subjects compared with normal-lean subjects. PMI 5011 treatment reduced basal phosphorylation of Akt and enhanced insulin-stimulated phosphorylation of Akt in the presence of cytokines in human myotubes. PMI 5011 treatment led to an inhibition of cytokine-induced activation of inflammatory signalling pathways such as Erk1/2 and IkBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha)-NFkB and moreover, NFkB target gene expression, possibly by preventing further propagation of the inflammatory response within muscle tissue. CONCLUSIONS: PMI 5011 improved insulin sensitivity in diabetic-obese myotubes to the level of normal-lean myotubes despite the presence of pro-inflammatory cytokines.
AIMS: Bioactives of Artemisia dracunculus L. (termed PMI 5011) have been shown to improve insulin action by increasing insulin signalling in skeletal muscle. However, it was not known if PMI 5011's effects are retained during an inflammatory condition. We examined the attenuation of insulin action and whether PMI 5011 enhances insulin signalling in the inflammatory environment with elevated cytokines. METHODS: Muscle cell cultures derived from lean, overweight and diabetic-obese subjects were used. Expression of pro-inflammatory genes and inflammatory response of human myotubes were evaluated by real-time polymerase chain reaction (RT-PCR). Insulin signalling and activation of inflammatory pathways in human myotubes were evaluated by multiplex protein assays. RESULTS: We found increased gene expression of monocyte chemoattractant protein 1 (MCP1) and TNFα (tumour necrosis factor alpha), and basal activity of the NFkB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in myotubes derived from diabetic-obese subjects as compared with myotubes derived from normal-lean subjects. In line with this, basal Akt phosphorylation (Ser473) was significantly higher, while insulin-stimulated phosphorylation of Akt (Ser473) was lower in myotubes from normal-overweight and diabetic-obese subjects compared with normal-lean subjects. PMI 5011 treatment reduced basal phosphorylation of Akt and enhanced insulin-stimulated phosphorylation of Akt in the presence of cytokines in human myotubes. PMI 5011 treatment led to an inhibition of cytokine-induced activation of inflammatory signalling pathways such as Erk1/2 and IkBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha)-NFkB and moreover, NFkB target gene expression, possibly by preventing further propagation of the inflammatory response within muscle tissue. CONCLUSIONS:PMI 5011 improved insulin sensitivity in diabetic-obese myotubes to the level of normal-lean myotubes despite the presence of pro-inflammatory cytokines.
Authors: Benjamin P Fairfax; Emma E Davenport; Seiko Makino; Adrian V S Hill; Fredrik O Vannberg; Julian C Knight Journal: J Immunol Date: 2011-01-31 Impact factor: 5.422
Authors: Clara Crescioli; Mariangela Sottili; Paolo Bonini; Lorenzo Cosmi; Paola Chiarugi; Paola Romagnani; Gabriella B Vannelli; Marta Colletti; Andrea M Isidori; Mario Serio; Andrea Lenzi; Luigi Di Luigi Journal: Eur J Cell Biol Date: 2011-12-15 Impact factor: 4.492
Authors: Yongmei Yu; Charlotte Simmler; Peter Kuhn; Alexander Poulev; Ilya Raskin; David Ribnicky; Z Elizabeth Floyd; Guido F Pauli Journal: J Nat Prod Date: 2019-12-09 Impact factor: 4.050
Authors: Igor A Schepetkin; Svetlana V Kushnarenko; Gulmira Özek; Liliya N Kirpotina; Gulzhakhan A Utegenova; Yuriy A Kotukhov; Alevtina N Danilova; Temel Özek; K Hüsnü Can Başer; Mark T Quinn Journal: J Agric Food Chem Date: 2015-05-19 Impact factor: 5.279
Authors: Bolormaa Vandanmagsar; Jaycob D Warfel; Shawna E Wicks; Sujoy Ghosh; J Michael Salbaum; David Burk; Olga S Dubuisson; Tamra M Mendoza; Jingying Zhang; Robert C Noland; Randall L Mynatt Journal: Cell Rep Date: 2016-05-12 Impact factor: 9.423
Authors: Yongmei Yu; Tamra M Mendoza; David M Ribnicky; Alexander Poulev; Robert C Noland; Randall L Mynatt; Ilya Raskin; William T Cefalu; Z Elizabeth Floyd Journal: Mol Nutr Food Res Date: 2018-04-03 Impact factor: 5.914
Authors: B Vandanmagsar; Y Yu; C Simmler; T N Dang; P Kuhn; A Poulev; D M Ribnicky; G F Pauli; Z E Floyd Journal: Biomed Pharmacother Date: 2021-09-23 Impact factor: 6.529
Authors: Jun Wang; Adelaida Esteban Fernández; Simoni Tiano; Jing Huang; Elizabeth Floyd; Alexander Poulev; David Ribnicky; Giulio M Pasinetti Journal: Oxid Med Cell Longev Date: 2018-05-13 Impact factor: 6.543
Authors: Timothy D Allerton; Greg M Kowalski; James Stampley; Brian A Irving; John R B Lighton; Z Elizabeth Floyd; Jacqueline M Stephens Journal: Med Sci Sports Exerc Date: 2021-04-01